The quarter cleared the bar by a wide margin. Revenue of $23.0 billion was roughly 11% above the published consensus of about $20.7 billion, while non-GAAP EPS of $8.38 was far above the roughly $6.1-$6.6 expected range. This was not simply year-over-year growth against an easy comparison: Lilly exceeded the standing quarterly expectation despite already elevated assumptions for its obesity and diabetes franchises. (Second-Quarter Financial Highlights)
| Metric | Q2 2026 actual | Q2 2025 | Standing expectation / prior outlook |
|---|---|---|---|
| Revenue | $22.97B | $15.56B | Published consensus: ~$20.7B (Second-Quarter Financial Highlights) |
| Diluted EPS, reported | $7.94 | $6.29 | — (Income Statement) |
| Diluted EPS, non-GAAP | $8.38 | $6.31 | Published consensus: ~$6.1-$6.6 (Non-GAAP EPS reconciliation) |
| Mounjaro revenue | $9.94B | $5.20B | +91% year over year (Selected Products) |
| Zepbound revenue | $4.93B | $3.38B | +46% year over year (Selected Products) |
| Full-year revenue outlook | $85B-$87B | Prior: $82B-$85B | Midpoint raised $2.5B (2026 Financial Guidance) |
| Full-year non-GAAP EPS outlook | $35.50-$36.50 | Prior: $35.50-$37.00 | Midpoint lowered $0.25 (2026 Financial Guidance) |
Demand remained stronger than the market had penciled in, led by the two tirzepatide brands. Mounjaro and Zepbound together produced $14.9 billion of quarterly sales, up 72% year over year, and accounted for roughly two-thirds of total revenue. International Mounjaro sales more than doubled as volume expanded, although China reimbursement reduced realized prices. In the U.S., strong demand also outweighed price pressure, including lower Zepbound cash-pay pricing. The important read is that volume growth—not price—is carrying the upside, making the revenue beat more durable than a one-off pricing benefit. (Selected Products; Revenue discussion)
The guidance change confirms a better underlying operating picture—but acquisitions absorb the EPS benefit. Revenue guidance rose to $85B-$87B and performance-margin guidance increased by 2 percentage points at both ends. Management says underlying business momentum added $2.78 per share at the midpoint, but recent business-development activity created $3.03 per share of acquired in-process R&D charges. The result: the reported non-GAAP EPS range moved down modestly at the midpoint and lost $0.50 from its top end. That does not negate the operating beat, but it means investors should separate stronger core demand from the accounting cost of buying pipeline assets. (2026 Financial Guidance; Non-GAAP EPS reconciliation)
Margins improved even with meaningful price concessions and investment. Reported gross margin rose to 85.8% from 84.3%, helped by production efficiencies and product mix. Revenue grew 48%, faster than R&D spending (+14%) and marketing, selling and administrative expense (+25%), supporting the higher margin outlook. Against expectations, this matters because it shows the sales upside is translating into operating leverage rather than being fully consumed by capacity, commercialization, and pipeline spending. (Gross Margin reconciliation; Income Statement)
The main offset is not weak demand but a more acquisition-heavy cost base. Q2 included $2.78 billion of acquired IPR&D expense and $703 million of acquisition, integration, and restructuring-related charges, associated largely with recently closed deals. Those costs held reported EPS growth to 26% even as revenue climbed 48%. The filing also adds future-pipeline optionality—retatrutide’s obesity data package is complete for planned 2027 submissions—but the near-term financial takeaway is clear: a substantial operating and revenue beat, partly diluted in full-year EPS presentation by deliberate deal spending rather than deterioration in the core business. (Income Statement; Business Development activity; Pipeline highlights)
Read the original 8-K on SEC EDGAR ↗